Aralez sues Teva over Yosprala aspirin patents

US-based drugs company Aralez Pharmaceuticals has filed a patent infringement complaint against Teva centring on the drug Yosprala (aspirin and omeprazole), a delayed-release aspirin.

The case,  filed Monday, January 23 at the US District Court for the Eastern District of Texas, Marshall Division, was brought to court after Teva filed an Abbreviated New Drug Application with the Food and Drug Administration seeking approval to market a generic version of Yosprala.

The patents involved are US numbers 6,926,907; 8,206,741; 9,364,439; and 9,539,214.

Aralez has asked the court for a judgment that Teva has infringed the four patents.

It has also asked for a permanent injunction enjoining Teva from bringing the generic product to market, as well as an award of costs and expenses.